Washington, D.C. – Norman C. Selby, senior managing director at Perseus LLC, a private equity firm with offices in D.C. and New York, has been elected to the Board of Trustees of the National Parks Conservation Association (NPCA). The board is the governing body for the nonprofit, which is the nation’s leading voice for national parks.
“Norman Selby is a terrific addition to NPCA’s board,” said NPCA President Tom Kiernan. “He is a wonderful park advocate and extremely business savvy. He will play a significant role in the future of our organization and the national parks.”
Before joining Perseus, Selby was president and CEO of TransForm Pharmaceuticals, a specialty pharmaceutical company. He was also an executive vice president at Citigroup/Citicorp from 1997-2000. Selby spent the bulk of his career at McKinsey & Company, where he was director (senior partner) in the firm’s New York office.
Selby is a member of the board of directors of NanoBio Corporation, Ascenta Therapeutics, Inc., and Perseus Books, LLC. He was a director of Millenium Pharmaceuticals (MLNM) from 2000-2008, and chairman of Windover Information from 2004-2008. Mr. Selby also serves on the board of trustees of the Central Park Conservancy, the Memorial Sloan-Kettering Cancer Center and the Ralph Lauren Center for Cancer Care and Prevention, all based in New York City.
Since 1919, the nonpartisan National Parks Conservation Association has been the leading voice of the American people in the fight to safeguard our National Park System. NPCA, its members, and partners work together to protect the park system and preserve our nation’s natural, historical, and cultural heritage for generations to come.
###
